Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Achondroplasia · Amyloid Cardiomyopathy, Transthyretin-Related · BBOT

BridgeBio Oncology Therapeutics

BridgeBio Oncology Therapeutics trial registry — 37 ClinicalTrials.gov studies with program phase, status, and indication context.

Website Investor relations
256 E Grand Ave, Suite 104, South San Francisco, California 94080, US HQ
103 Employees
Public company Type
BBOT · NYSE Ticker
Company details
Status
Public
HQ
256 E Grand Ave, Suite 104, South San Francisco, California 94080, US
Employees
103
Programs
34
Drugs
14
Patents
1
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Trials

BridgeBio Oncology Therapeutics clinical trials

Registry index of 37 ClinicalTrials.gov studies linked to BridgeBio Oncology Therapeutics programs — each row shows trial ID, program name, phase, status, and indication.

BridgeBio Oncology Therapeutics trial registry — 37 ClinicalTrials.gov studies with program phase, status, and indication context.

Recent trial activity

8 updates

Latest clinical program signals indexed for BridgeBio Oncology Therapeutics.

  1. Infigratinib — Phase 3

    Clinical update

  2. Infigratinib is provided as a single dose of minitablets for oral administration — Phase 2

    Clinical update

  3. Infigratinib — Phase 2

    Clinical update

  4. Infigratinib — Phase 1

    Clinical update

  5. Infigratinib — Phase 1

    Clinical update

  6. Infigratinib — Phase 1

    Clinical update

  7. Infigratinib — Phase 2

    Clinical update

  8. AG10 oral tablet — Phase 1

    Clinical update

Trial registry

37 studies

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.